SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $5,338 | -$10,114 | -$5,197 | -$11,395 |
| Dep. & Amort. | $765 | $775 | $778 | $786 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $627 | $613 | $0 |
| Change in WC | $1,624 | $943 | $1,065 | -$1,884 |
| Other Non-Cash | -$20,777 | $618 | -$5,056 | $3,222 |
| Operating Cash Flow | -$13,050 | -$7,152 | -$7,797 | -$9,271 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | $0 | -$55 |
| Net Acquisitions | $0 | $0 | $1 | $0 |
| Inv. Purchases | -$129,869 | -$52 | -$71 | -$1,309 |
| Inv. Sales/Matur. | $0 | $5,250 | $4,742 | $10,695 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$129,869 | $5,198 | $4,671 | $9,331 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $168,694 | -$174 | -$172 | -$19 |
| Stock Issued | $0 | $0 | $0 | -$0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$5 | $0 | -$2 | -$25 |
| Financing Cash Flow | $168,689 | -$174 | -$174 | -$44 |
| Forex Effect | -$38 | $179 | $43 | -$289 |
| Net Chg. in Cash | $25,732 | -$1,948 | -$3,258 | -$273 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $3,692 | $5,640 | $8,898 | $9,171 |
| End Cash | $29,425 | $3,692 | $5,640 | $8,898 |
| Free Cash Flow | -$13,050 | -$7,152 | -$7,797 | -$9,326 |